Search Results - "Weidenbacher, Payton A."

Efficient evolution of human antibodies from general protein language models by Hie, Brian L., Shanker, Varun R., Xu, Duo, Bruun, Theodora U. J., Weidenbacher, Payton A., Tang, Shaogeng, Wu, Wesley, Pak, John E., Kim, Peter S.

“…Natural evolution must explore a vast landscape of possible sequences for desirable yet rare mutations, suggesting that learning from natural evolutionary…”
Get full text

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates by Weidenbacher, Payton A.-B., Sanyal, Mrinmoy, Friedland, Natalia, Tang, Shaogeng, Arunachalam, Prabhu S., Hu, Mengyun, Kumru, Ozan S., Morris, Mary Kate, Fontenot, Jane, Shirreff, Lisa, Do, Jonathan, Cheng, Ya-Chen, Vasudevan, Gayathri, Feinberg, Mark B., Villinger, Francois J., Hanson, Carl, Joshi, Sangeeta B., Volkin, David B., Pulendran, Bali, Kim, Peter S.

“…While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting…”
Get full text

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine by Li, Chunfeng, Lee, Audrey, Grigoryan, Lilit, Arunachalam, Prabhu S., Scott, Madeleine K. D., Trisal, Meera, Wimmers, Florian, Sanyal, Mrinmoy, Weidenbacher, Payton A., Feng, Yupeng, Adamska, Julia Z., Valore, Erika, Wang, Yanli, Verma, Rohit, Reis, Noah, Dunham, Diane, O’Hara, Ruth, Park, Helen, Luo, Wei, Gitlin, Alexander D., Kim, Peter, Khatri, Purvesh, Nadeau, Kari C., Pulendran, Bali

“…Despite the success of the BNT162b2 mRNA vaccine, the immunological mechanisms that underlie its efficacy are poorly understood. Here we analyzed the innate…”
Get full text

Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope by Weidenbacher, Payton A., Kim, Peter S.

“…In creating vaccines against infectious agents, there is often a desire to direct an immune response toward a particular conformational epitope on an antigen…”
Get full text

Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors by Weidenbacher, Payton A.-B., Waltari, Eric, de los Rios Kobara, Izumi, Bell, Benjamin N., Morris, Mary Kate, Cheng, Ya-Chen, Hanson, Carl, Pak, John E., Kim, Peter S.

“…Omicron and its subvariants have rendered most authorized monoclonal antibody-based treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…”
Get full text

A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV‑2 in Mice by Powell, Abigail E, Zhang, Kaiming, Sanyal, Mrinmoy, Tang, Shaogeng, Weidenbacher, Payton A, Li, Shanshan, Pham, Tho D, Pak, John E, Chiu, Wah, Kim, Peter S

“…The development of a safe and effective SARS-CoV-2 vaccine is a public health priority. We designed subunit vaccine candidates using self-assembling ferritin…”
Get full text

Vaccine design via antigen reorientation by Xu, Duo, Carter, Joshua J., Li, Chunfeng, Utz, Ashley, Weidenbacher, Payton A. B., Tang, Shaogeng, Sanyal, Mrinmoy, Pulendran, Bali, Barnes, Christopher O., Kim, Peter S.

“…A major challenge in creating universal influenza vaccines is to focus immune responses away from the immunodominant, variable head region of hemagglutinin…”
Get full text

Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates by Weidenbacher, Payton A.-B., Sanyal, Mrinmoy, Friedland, Natalia, Tang, Shaogeng, Arunachalam, Prabhu S., Hu, Mengyun, Kumru, Ozan S., Morris, Mary Kate, Fontenot, Jane, Shirreff, Lisa, Do, Jonathan, Cheng, Ya-Chen, Vasudevan, Gayathri, Feinberg, Mark B., Villinger, Francois J., Hanson, Carl, Joshi, Sangeeta B., Volkin, David B., Pulendran, Bali, Kim, Peter S.

Get full text

Bringing immunofocusing into focus by Musunuri, Sriharshita, Weidenbacher, Payton A. B., Kim, Peter S.

“…Immunofocusing is a strategy to create immunogens that redirect humoral immune responses towards a targeted epitope and away from non-desirable epitopes…”
Get full text

Engineering a SARS-CoV‑2 Vaccine Targeting the Receptor-Binding Domain Cryptic-Face via Immunofocusing by Bruun, Theodora U. J., Do, Jonathan, Weidenbacher, Payton A.-B., Utz, Ashley, Kim, Peter S.

“…The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is the main target of neutralizing antibodies. Although they are infrequently elicited during…”
Get full text

Targeted glycan degradation potentiates the anticancer immune response in vivo by Gray, Melissa A., Stanczak, Michal A., Mantuano, Natália R., Xiao, Han, Pijnenborg, Johan F. A., Malaker, Stacy A., Miller, Caitlyn L., Weidenbacher, Payton A., Tanzo, Julia T., Ahn, Green, Woods, Elliot C., Läubli, Heinz, Bertozzi, Carolyn R.

“…Currently approved immune checkpoint inhibitor therapies targeting the PD-1 and CTLA-4 receptor pathways are powerful treatment options for certain cancers;…”
Get full text

New-onset IgG autoantibodies in hospitalized patients with COVID-19 by Chang, Sarah Esther, Feng, Allan, Meng, Wenzhao, Apostolidis, Sokratis A., Mack, Elisabeth, Artandi, Maja, Barman, Linda, Bennett, Kate, Chakraborty, Saborni, Chang, Iris, Cheung, Peggie, Chinthrajah, Sharon, Dhingra, Shaurya, Do, Evan, Finck, Amanda, Gaano, Andrew, Geßner, Reinhard, Giannini, Heather M., Gonzalez, Joyce, Greib, Sarah, Gündisch, Margrit, Hsu, Alex Ren, Kuo, Alex, Manohar, Monali, Mao, Rong, Neeli, Indira, Neubauer, Andreas, Oniyide, Oluwatosin, Powell, Abigail E., Puri, Rajan, Renz, Harald, Schapiro, Jeffrey, Weidenbacher, Payton A., Wittman, Richard, Ahuja, Neera, Chung, Ho-Ryun, Jagannathan, Prasanna, James, Judith A., Kim, Peter S., Meyer, Nuala J., Nadeau, Kari C., Radic, Marko, Robinson, William H., Singh, Upinder, Wang, Taia T., Wherry, E. John, Skevaki, Chrysanthi, Luning Prak, Eline T., Utz, Paul J.

“…COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein…”
Get full text

Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold by Weidenbacher, Payton A.-B., Rodriguez-Rivera, Frances P., Sanyal, Mrinmoy, Visser, Joshua A., Do, Jonathan, Bertozzi, Carolyn R., Kim, Peter S.

“…Vaccine scaffolds and carrier proteins increase the immunogenicity of subunit vaccines. Here, we developed, characterized, and demonstrated the efficacy of a…”
Get full text